There is considerable interest in developing new quantitative imaging methods to monitor and predict breast cancer response to neoadjuvant chemotherapy, both prior to and as early as possible during the course of treatment. Diffuse optical spectroscopic imaging (DOSI) allows patients to be followed from baseline through treatment and surgery with a cost-effective, bedside, handheld scanning probe. In this work, we propose to significantly advance the development of harmonized DOSI technology platform and evaluate its performance in five clinical sites on up to 90 neoadjuvant chemotherapy patients. In preliminary patient studies, DOSI quantitative functional endpoints have been shown to be effective in predicting tumor response to chemotherapy within the first week of a two - four month treatment regimen. In the proposed work we will optimize and improve DOSI functionality, standardize clinical measurement and analysis procedures, and evaluate whether DOSI can be used with equivalent overall performance by different operators. Our long-term goal is to identify quantitative clinical endpoints that can be used to inform medical decisions on chemotherapy regimen, duration, and timing of surgery. These non-invasive endpoints are obtained rapidly with no risk/discomfort and could be used as surrogate markers of pathologic response, an established indicator of long-term survival. An archived database of breast cancer spectroscopic markers will be made available to the research community in order to further facilitate new technology development and enhance our understanding of breast cancer chemotherapy. Few technologies have bridged the gap between laboratory prototype and clinically disseminated cancer imaging system. We are now poised to make this transition by creating a standardized and validated DOSI platform, necessary next steps in the translational research process. Ultimately this work is expected to lead to a bedside optical imaging technology that can be used to improve patient outcome by maximizing therapeutic response, minimizing unnecessary toxicity, and optimizing clinical decision-making.

Public Health Relevance

We propose to advance the development of a portable, bedside optical imaging technology capable of monitoring and predicting patient response to breast cancer neoadjuvant chemotherapy. The technology, Diffuse Optical Spectroscopic Imaging (DOSI), will be evaluated in a multi-site study designed to validate optical endpoints of clinical response.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA142989-03
Application #
8207928
Study Section
Biomedical Imaging Technology Study Section (BMIT)
Program Officer
Baker, Houston
Project Start
2010-01-01
Project End
2013-12-31
Budget Start
2012-01-01
Budget End
2013-12-31
Support Year
3
Fiscal Year
2012
Total Cost
$576,227
Indirect Cost
$199,608
Name
University of California Irvine
Department
None
Type
Organized Research Units
DUNS #
046705849
City
Irvine
State
CA
Country
United States
Zip Code
92697
Leproux, Anais; Cerussi, Albert E; Tanamai, Wendy et al. (2011) Impact of contralateral and ipsilateral reference tissue selection on self-referencing differential spectroscopy for breast cancer detection. J Biomed Opt 16:116019
Lin, Yuting; Thayer, Dave; Nalcioglu, Orhan et al. (2011) Tumor characterization in small animals using magnetic resonance-guided dynamic contrast enhanced diffuse optical tomography. J Biomed Opt 16:106015
Santoro, Ylenia; Leproux, Anais; Cerussi, Albert et al. (2011) Breast cancer spatial heterogeneity in near-infrared spectra and the prediction of neoadjuvant chemotherapy response. J Biomed Opt 16:097007
Stojadinovic, Alexander; Summers, Thomas A; Eberhardt, John et al. (2011) Consensus recommendations for advancing breast cancer: risk identification and screening in ethnically diverse younger women. J Cancer 2:210-27
Cerussi, Albert E; Tanamai, Vaya W; Hsiang, David et al. (2011) Diffuse optical spectroscopic imaging correlates with final pathological response in breast cancer neoadjuvant chemotherapy. Philos Trans A Math Phys Eng Sci 369:4512-30
Roblyer, Darren; Ueda, Shigeto; Cerussi, Albert et al. (2011) Optical imaging of breast cancer oxyhemoglobin flare correlates with neoadjuvant chemotherapy response one day after starting treatment. Proc Natl Acad Sci U S A 108:14626-31
Lin, Y; Ghijsen, M T; Gao, H et al. (2011) A photo-multiplier tube-based hybrid MRI and frequency domain fluorescence tomography system for small animal imaging. Phys Med Biol 56:4731-47
Kukreti, Shwayta; Cerussi, Albert E; Tanamai, Wendy et al. (2010) Characterization of metabolic differences between benign and malignant tumors: high-spectral-resolution diffuse optical spectroscopy. Radiology 254:277-84
Cerussi, Albert E; Tanamai, Vaya W; Mehta, Rita S et al. (2010) Frequent optical imaging during breast cancer neoadjuvant chemotherapy reveals dynamic tumor physiology in an individual patient. Acad Radiol 17:1031-9
Tanamai, Wendy; Chen, Cynthia; Siavoshi, Sara et al. (2009) Diffuse optical spectroscopy measurements of healing in breast tissue after core biopsy: case study. J Biomed Opt 14:014024

Showing the most recent 10 out of 11 publications